Evidence map›Paper›PMID 42350451›Full record

ReviewNPJ breast cancer2026

Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.

Martin Widschwendter, Rita Schmutzler, Nora Pashayan, Jelle Wesseling, Marc Tischkowitz, Michal Zikan, Miranda Steenbeek, Marike Gabrielson, Christian F Singer, Cathrin Brisken and 18 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Martin WidschwendterThe Daffodil Centre, Cancer Council New South Wales and University of Sydney, Sydney, Australia. Martin.Widschwendter@sydney.edu.au.
Rita SchmutzlerCentre for Hereditary Breast and Ovarian Cancer and Centre for Integrated Oncology (CIO), Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Jelle WesselingDivision of Molecular Pathology and Department of Pathology, Netherlands Cancer Institute, Amsterdam & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Marc TischkowitzDepartment of Genomic Medicine, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Michal ZikanDepartment of Gynecology and Obstetrics, Bulovka University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Miranda SteenbeekDepartment of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Marike GabrielsonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Christian F SingerDepartment of Obstetrics and Gynaecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Cathrin BriskenISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.
Rebecca GompertsWomen on Waves, Amsterdam, Netherlands.
Sharon CameronChalmers Centre for Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK.
Dafydd Gareth EvansUniversity of Manchester, School of Biological Sciences, Division of Evolution, Infection and Genomics, Manchester, Greater, Manchester, UK.
Andri PapakonstantinouDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Marc BuyseIDDI (International Drug Development Institute), Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Hasselt, Belgium.
Kerstin RhiemCentre for Hereditary Breast and Ovarian Cancer and Centre for Integrated Oncology (CIO), Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Mateja KrajcCancer Genetics Clinic, Institute of Oncology Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia; University of Ljubljana, Kongresni trg, Ljubljana, Slovenia.
Charlotte VavourakisEuropean Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
Elisa RedlEuropean Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
Chiara HerzogEuropean Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
James BarrettEuropean Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
Mohammed Fatih RasulDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Deborah UtjésDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Kiriaki PapaikonomouDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Angelique Flöter RådestadDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Athanasios ZouzosDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Twana AlkasaliasDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Kristina Gemzell-DanielssonDepartment for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Funding

European Research Council BRCA PREVENT, 101113534UCSF RISE UP for Breast Cancer no specific grant number
6 · The paper itself

Abstract

Women with germline BRCA1 pathogenic variants face a very high risk of early-onset triple-negative breast cancer (TNBC), with risk-reducing mastectomy currently the only established preventive option. Emerging evidence suggests aberrant progesterone signalling contributes to TNBC risk, while preclinical studies indicate progesterone receptor modulators such as mifepristone may substantially reduce cancer development. DNA methylation-based markers reflecting field cancerization and replicative age could enable real-time monitoring of preventive efficacy and support an individualised primary prevention approach.

Identifiers

PMID42350451
PMCPMC13661513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.